VIDA is the established leader in quantitative pulmonary imaging analysis offering a unique lung imaging evaluation as a service to aid in the early detection, diagnosis, and treatment evaluation of pulmonary diseases.
VIDA increases the value of each imaging exam by providing image-based screening, diagnostic and therapy planning solutions evaluated in a strict, quality controlled environment to optimize personalized patient management for the pulmonary clinician at the point of care.
ViDA Diagnostics was founded in 2004 and is headquartered in Coralville, Iowa.
VIDA provides the new standard of pulmonary care by using AI-powered CT imaging software and services to aid the early detection, evaluation, and treatment planning of patients with or at risk of lung diseases, including emphysema and airway obstructive diseases (COPD), asthma, interstitial lung disease, and lung cancer.
VIDA's software and services are FDA cleared, CE-marked, Health Canada licensed and TGA registered for clinical use in the US, European Economic Area, Canada and Australia. Its LungPrint® is an AI-powered suite of products and services used to uniquely profile and manage the patient with, or at-risk of, lung diseases.
VIDA Diagnostics is backed by First Analysis Corporation, Next Level Ventures, Blue Heron Capital, UnityPoint Health Ventures and others. The company raised $11M in its Series C round on Mar 12, 2020. This brings VIDA's total funding to $20.4M to date.